T-mab Bio

T-mab Bio is a South Korean biotechnology company specializing in the discovery and development of next-generation antibody therapeutics for oncology. The company leverages its proprietary T-mab platform to engineer high-affinity monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). Its research pipeline is primarily focused on addressing solid tumors with high unmet medical needs, including gastric and pancreatic cancers, by targeting validated antigens such as Claudin 18.2 and Mesothelin. T-mab Bio aims to develop best-in-class and first-in-class biologics through precision engineering and innovative therapeutic designs. The company is actively advancing its lead candidates through the pre-clinical stage toward clinical evaluation.